Free Trial

Evogene Q3 2024 Earnings Report

Evogene logo
$1.81 +0.03 (+1.87%)
As of 03:53 PM Eastern

Evogene EPS Results

Actual EPS
-$1.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evogene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evogene Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

Evogene Earnings Headlines

StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)
Evogene-Aktie erreicht 52-Wochen-Tief bei 1,25 US-Dollar
AAPL: Double Your Returns in 24 Hours?
Trader Chris Pulver is diving deep into the inner workings of Wall Street... To reveal a trading method he’s kept under wraps for years. You see… Thanks to “liquidity levels” which show us Wall Street’s biggest undercover buy orders in real time… This method has shown the ability to DOUBLE our returns…
Evogene price target lowered to $5 from $12 at Lake Street
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
See More Evogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evogene and other key companies, straight to your email.

About Evogene

Evogene (NASDAQ:EVGN), together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

View Evogene Profile

More Earnings Resources from MarketBeat